Dudediligence.

Tango Therapeutics, Inc

TNGXNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$11.6MSep ’24$4.1MDec ’24$5.4MMar ’25$3.2MJun ’25$53.8MSep ’25$0.00Dec ’25$0.00Mar ’26$0.00Jun ’26
Net income, by quarter
−$29.2MSep ’24−$37.7MDec ’24−$39.9MMar ’25−$38.9MJun ’25$15.9MSep ’25−$38.8MDec ’25−$45.5MMar ’26−$55.3MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$37.0M$24.9M$36.5M$42.1M$62.4M
Operating income−$58.2M−$111.1M−$114.2M−$145.6M−$111.3M
Net income−$58.2M−$108.2M−$101.7M−$130.3M−$101.6M
Operating cash flow−$59.5M−$109.1M−$118.0M−$131.5M−$138.9M
Free cash flow−$61.4M−$116.8M−$119.5M−$132.3M−$139.9M
Cash$142.7M$60.0M$66.4M$69.5M$112.3M
Shares outstanding87.6M88.2M102.2M107.7M135.9M